|
| 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 |
| 34135391 | A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce. | Sci Rep | 2021 |
| 29759569 | Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. | Crit Rev Oncol Hematol | 2018 |
| 29728319 | Current status and trends in the diagnostics of AML and MDS. | Blood Rev | 2018 |
| 28557976 | Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. | Br J Cancer | 2017 |
| 28222336 | A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. | Leuk Res | 2017 |
| 28399885 | Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. | J Hematol Oncol | 2017 |
| 28472036 | Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients. | PLoS One | 2017 |
| 28492898 | Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. | JAMA | 2017 |
| 29045535 | SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. | Ann Oncol | 2017 |
| 29018576 | Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice. | ESMO Open | 2017 |
| 28751759 | A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories. | Br J Cancer | 2017 |
| 26220041 | Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN. | Leukemia | 2016 |
| 27741277 | Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes. | PLoS One | 2016 |
| 27168466 | The role of the RAS pathway in iAMP21-ALL. | Leukemia | 2016 |
| 26992948 | Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. | Haematologica | 2016 |
| 26867670 | Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. | Leukemia | 2016 |
| 26918901 | Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). | PLoS One | 2016 |
| 25367136 | Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. | J Cancer Res Clin Oncol | 2015 |
| 26630574 | A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. | PLoS One | 2015 |
| 25659728 | Mutational profiling in patients with MDS: ready for every-day use in the clinic? | Best Pract Res Clin Haematol | 2015 |
| 25527566 | Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. | Haematologica | 2015 |
| 25586593 | Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. | Nat Commun | 2015 |
| 23958918 | Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. | Leukemia | 2014 |
| 25212276 | Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. | Leukemia | 2014 |
| 24829203 | TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. | Blood | 2014 |
| 24925730 | A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next-generation sequencing can be revealed by comparative bioinformatic analyses. | Br J Haematol | 2014 |
| 24619868 | Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. | Genes Chromosomes Cancer | 2014 |
| 24523240 | Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. | Blood | 2014 |
| 24693539 | TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations. | Biomed Res Int | 2014 |
| 24704494 | Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. | Cell Stem Cell | 2014 |
| 24363398 | Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. | Blood | 2014 |
| 24493299 | Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. | Genes Chromosomes Cancer | 2014 |
| 24413067 | BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. | Blood Cancer J | 2014 |
| 24497565 | Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases. | Haematologica | 2014 |
| 24113472 | SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. | Leukemia | 2014 |
| 24056881 | The role of different genetic subtypes of CEBPA mutated AML. | Leukemia | 2014 |
| 24220272 | Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. | Leukemia | 2014 |
| 24144312 | Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. | Leuk Lymphoma | 2014 |
| 24164563 | Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. | Eur J Haematol | 2014 |
| 22814295 | GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. | Leukemia | 2013 |
| 24052547 | EZH2 mutations are frequent and represent an early event in follicular lymphoma. | Blood | 2013 |
| 23860447 | Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. | Leukemia | 2013 |
| 23958953 | Comprehensive mutational profiling in advanced systemic mastocytosis. | Blood | 2013 |
| 23680131 | Robustness of amplicon deep sequencing underlines its utility in clinical applications. | J Mol Diagn | 2013 |
| 23648669 | Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. | Leukemia | 2013 |
| 23794064 | Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. | Blood | 2013 |
| 23383300 | Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases. | PLoS One | 2013 |
| 23535558 | High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia. | Leukemia | 2013 |
| 23521373 | CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis. | Br J Haematol | 2013 |